These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 31152368)

  • 21. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review.
    Pacchiarotti I; Tiihonen J; Kotzalidis GD; Verdolini N; Murru A; Goikolea JM; Valentí M; Aedo A; Vieta E
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):457-470. PubMed ID: 30770235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
    Ostuzzi G; Bertolini F; Del Giovane C; Tedeschi F; Bovo C; Gastaldon C; Nosé M; Ogheri F; Papola D; Purgato M; Turrini G; Correll CU; Barbui C
    Am J Psychiatry; 2021 May; 178(5):424-436. PubMed ID: 33596679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.
    Eum S; Schneiderhan ME; Brown JT; Lee AM; Bishop JR
    BMC Psychiatry; 2017 Jul; 17(1):238. PubMed ID: 28673279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review.
    Belge JB; Sabbe BGCC
    Expert Opin Pharmacother; 2024 Feb; 25(3):295-299. PubMed ID: 38465894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study.
    Magliocco F; de Filippis R; Aloi M; Staltari FA; Gaetano R; Segura-Garcia C; De Fazio P
    Int J Psychiatry Clin Pract; 2020 Jun; 24(2):201-207. PubMed ID: 32134336
    [No Abstract]   [Full Text] [Related]  

  • 26. Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia.
    Lauriello J; Weiden PJ; Gleeson CD; Shah A; Boulanger L; Jariwala-Parikh K; Hedgeman E; O'Sullivan AK
    CNS Drugs; 2021 Oct; 35(10):1123-1135. PubMed ID: 34546558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial.
    Kane JM; Schooler NR; Marcy P; Correll CU; Achtyes ED; Gibbons RD; Robinson DG
    JAMA Psychiatry; 2020 Dec; 77(12):1217-1224. PubMed ID: 32667636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
    San L; Estrada G; Oudovenko N; Vieta E
    BMC Psychiatry; 2017 Apr; 17(1):126. PubMed ID: 28376877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.
    Biagi E; Capuzzi E; Colmegna F; Mascarini A; Brambilla G; Ornaghi A; Santambrogio J; Clerici M
    Adv Ther; 2017 May; 34(5):1036-1048. PubMed ID: 28382557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report.
    Ballester-Gracia I; Pérez-Almarcha M; Galvez-Llompart A; Hernandez-Viadel M
    BMC Pharmacol Toxicol; 2019 Aug; 20(1):52. PubMed ID: 31462311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
    Turncliff R; Hard M; Du Y; Risinger R; Ehrich EW
    Schizophr Res; 2014 Nov; 159(2-3):404-10. PubMed ID: 25266547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
    Weiden PJ; Du Y; von Moltke L; Wehr A; Hard M; Marandi M; Walling DP
    CNS Drugs; 2020 Sep; 34(9):961-972. PubMed ID: 32621071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.
    Shirley M; Perry CM
    Drugs; 2014 Jul; 74(10):1097-110. PubMed ID: 24969315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.
    Hard ML; Mills RJ; Sadler BM; Turncliff RZ; Citrome L
    J Clin Psychopharmacol; 2017 Jun; 37(3):289-295. PubMed ID: 28350572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
    Correll CU; Kim E; Sliwa JK; Hamm W; Gopal S; Mathews M; Venkatasubramanian R; Saklad SR
    CNS Drugs; 2021 Jan; 35(1):39-59. PubMed ID: 33507525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016-March 2019.
    Peters L; Krogmann A; von Hardenberg L; Bödeker K; Nöhles VB; Correll CU
    Curr Psychiatry Rep; 2019 Nov; 21(12):124. PubMed ID: 31745659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches.
    Højlund M; Correll CU
    Expert Opin Pharmacother; 2023; 24(13):1463-1489. PubMed ID: 37345508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder.
    Yan T; Greene M; Chang E; Touya M; Broder MS
    J Comp Eff Res; 2018 Nov; 7(11):1083-1093. PubMed ID: 30129771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial.
    Kane JM; Schooler NR; Marcy P; Achtyes ED; Correll CU; Robinson DG
    J Clin Psychiatry; 2019 Apr; 80(3):. PubMed ID: 31050233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.